AACR Conference Coverage
Featured Articles
(Johns Hopkins Medicine) Apr 3, 2019 - Due to advances in treatment, an ever-increasing number of patients are living longer as metastatic cancer survivors. They and their doctors face a host of new challenges that require immediate attention. It used to be when you were diagnosed with metastatic cancer, you were told to get your...
Read Article
(BMS) Apr 2, 2019 - Bristol-Myers Squibb Company today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab). In the pooled analysis of the four...
Read Article
Latest Articles
April 05, 2019
April 04, 2019
April 04, 2019
April 03, 2019
April 03, 2019
April 03, 2019
April 03, 2019
April 03, 2019
View More
News Commentary
Editor Image
03 Apr, 2019 | by H. Jack West, MD
Nice to see further long-term survival data, really in keeping with what we've...
View Comment
Editor Image
02 Apr, 2019 | by Tomasz M. Beer, MD
A badly misleading title. This study could not determine if survival is...
View Comment
View More
Featured Videos
There are no videos.
OBR Blog
Facts first, then comments. Keynote -189: This phase III trial compared pembrolizumab (pembro), or placebo, plus... Read more
April 17, 2018
A pre-meeting webinar provided a glimpse of some of the key presentations at the upcoming annual meeting of the... Read more
March 16, 2018

OBR Tweets

Feb 20
H. Jack West, MD: The results with atezolizumab in this highly enriched subset echo the findings with pembrolizumab… https://t.co/KbOYjNqeHc

Feb 19
Howard S. Hochster, MD: Another "swing and a miss" in pancreatic cancer. Despite numerous trial of chemotherapy pl… https://t.co/mAuyJZE4fa

Feb 18
William McGivney, PhD: Every once in a while, in my columns, I mention that Rick Pazdur, MD of the FDA NEEDS to be… https://t.co/SgpegJSMWB

Feb 17
Nizar Tannir, MD, of @MDAndersonNews describes the 4 year follow up study of nivolumab + ipilimumab in RCC patients… https://t.co/RY6WXLDL1N

Feb 17
Bradley McGregor, MD @BradMcG04, of @DanaFarber on impressions of phase I/II study of oral HIF-2 α inhibitor MK-648… https://t.co/EPvkjmtsb4

Feb 17
David Quinn, MD, of @KeckMedUSC on impressions of phase I/II study of oral HIF-2 α inhibitor MK-6482 in patients wi… https://t.co/rBvAje1it1

Feb 17
Scott Tawaga, MD, of @WeillCornell on promising PSMA products in development for prostate cancer treatment #GU20 https://t.co/BLfI32lWzS

Feb 17
Tian Zhang, MD, MHS @TiansterZhang, of @DukeCancer elaborates on the PEDIGREE clinical study in advanced renal cell… https://t.co/kgdQPTsquK

Feb 17
Bradley McGregor, MD @BradMcG04, of @DanaFarber describes whether biomarkers will help guide treatment in advanced… https://t.co/2uejg888Ui

Feb 17
Michael Atkins, MD, of @LombardiCancer on follow up investigation of Checkmate 025 in renal cell carcinoma patients… https://t.co/2dyPZwc8dF